Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6537062 | 0.80 | ALDH1A1 (0.32) | TSHRLMNA | |
| SCHEMBL19426319 | 0.75 | — | — | |
| SCHEMBL2128079 | 0.75 | TSHR (0.50) | TSHRLMNA | |
| SCHEMBL20393509 | 0.74 | — | — | |
| SCHEMBL22054559 | 0.73 | ALDH1A1 (0.36) | TSHRLMNA | |
| SCHEMBL97780 | 0.72 | TSHR (0.56) | TSHRLMNA | |
| SCHEMBL22987326 | 0.71 | CNR1 (0.33) | TSHRLMNA | |
| Hydrochloric Acid SCHEMBL180144 | 0.70 | TSHR (0.53) | TSHRLMNA | |
| Hydrochloric Acid SCHEMBL1844352 | 0.70 | TSHR (0.53) | TSHRLMNA | |
| SCHEMBL24220981 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260061041-A1 | COMPOSITIONS AND METHODS FOR TREATING HEMOGLOBINOPATHIES | BEAM THERAPEUTICS INC. (US) | 2026-03-05 | — | — | US | disclosed |
| US-20240301444-A1 | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | PRIME MEDICINE, INC. | 2024-09-12 | — | — | US | disclosed |
| US-11952408-B2 | HPV-specific binding molecules | JUNO THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| CN-117835991-A | Chimeric costimulatory receptors, chemokine receptors and their use in cellular immunotherapy | 艾欧凡斯生物治疗公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-110036028-B | anti-IL 1-RAP antibodies | 坎塔吉亚有限责任公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-116322758-A | Nucleic acid-based combination vaccine | 库尔维科欧洲股份公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-101429260-B | Polymethacrylate, preparation method and application thereof | SHANGHAI INST APPLIED PHYSICS | 2010-12-01 | — | — | CN | disclosed |
| CN-101429260-A | Polymethacrylate, preparation method and application thereof | SHANGHAI INST APPLIED PHYSICS (CN) | 2009-05-13 | — | — | CN | disclosed |
| EP-1175395-A1 | METHOD OF PREPARING N,N'-DISUBSTITUTED-3,3'-DITHIODIPROPIONAMIDE AND METHOD OF PREPARING SUBSTITUTED 3-ISOTHIAZOLONE BY USING THE SAME | SK Chemicals Co., Ltd. (KR) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000059879-A1 | METHOD OF PREPARING N,N'-DISUBSTITUTED-3,3'-DITHIODIPROPIONAMIDE AND METHOD OF PREPARING SUBSTITUTED 3-ISOTHIAZOLONE BY USING THE SAME | SK CHEMICALS CO., LTD ET AL. (KR) | 2000-10-12 | — | — | WO | disclosed |
| EP-0095907-B1 | BIOCIDAL OR BIOSTATIC COMPOSITIONS CONTAINING 3-ISOTHIAZOLONES, THEIR METHOD OF PREPARATION AND THEIR USES | ROHM AND HAAS COMPANY (US) | 1988-04-27 | — | — | EP | disclosed |
| EP-0095907-A2 | Biocidal or biostatic compositions containing 3-isothiazolones, their method of preparation and their uses | ROHM AND HAAS COMPANY (US) | 1983-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260061041-A1 | COMPOSITIONS AND METHODS FOR TREATING HEMOGLOBINOPATHIES | BCDIN3D, ADAR, MTAP | TSHR 2199/4885LMNA 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.